$BMY
BMY · Healthcare
- Market cap
- —
- Volume
- —
- P/E
- —
- Day range
- — – —
- 52w range
- — – —
- Analyst target
- —
AI Summary
Generating a unique summary for BMY…
AI-generated for information only — not investment advice.
Share this ticker
$BMY Ken Griffin and 1 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/BMY
Company summary
Oncology and cardiology drugs.
Institutional ownership
Institutions hold —% · insiders —%
No institutional filings available for this ticker.
Hedge fund & billionaire activity
Insider transactions
No insider transactions reported.
Analyst ratings
Consensus score — (1 = strong buy, 5 = sell) · mean target —
No recent analyst actions.
Earnings
Next report: not scheduled
No earnings history available.
SEC filings
No filings indexed for this ticker.
Latest BMY news
- Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
Fri, 04 Sep 2026 21:45:03 +0000
- Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Fri, 04 Sep 2026 19:48:43 +0000
- Sector Update: Healthcare Stocks Decline Friday Afternoon
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H
Fri, 04 Sep 2026 17:41:05 +0000
- Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns
Bristol Myers Squibb (BMY) has told regulators, researchers and patient groups in early June that it
Fri, 04 Sep 2026 09:10:29 +0000
- Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
Despite Bristol-Myers Squibb's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Thu, 03 Sep 2026 15:39:52 +0000
- Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds
Program yields evidence supporting $14.1 million in savings by keeping patients out of the hospitalALEXANDRIA, VA / ACCESS Newswire / September 3, 2026 / Originally published on NCPA.
Thu, 03 Sep 2026 13:00:00 +0000
- What Does Bristol Myers Squibb (BMY) Trial Pause Mean For Its Pipeline?
Bristol Myers Squibb (NYSE:BMY) has paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following emerging safety concerns. The voluntary pause comes after inflammatory side effects were detected during ongoing safety surveillance in the program. The move raises fresh questions around the risk profile of cell-based therapies in autoimmune diseases, as well as the pace of Bristol Myers Squibb's clinical pipeline. For readers interested in more ideas in this corner...
Thu, 03 Sep 2026 04:31:19 +0000
- Bristol Myers Squibb (BMY) Gains On Camzyos Data, Is The Upside Already Priced In?
Bristol-Myers Squibb (BMY) is back in focus after presenting long term Camzyos data from the EXPLORER-LTE cohort at the 2026 European Society of Cardiology Congress in Munich. Against this backdrop, Bristol-Myers Squibb’s share price has moved to US$66.92, with a 90 day share price return of 22.3% and a year to date share price return of 25.2%, while the 1 year total shareholder return of 47.9% points to stronger gains once dividends are included. Recent momentum has coincided with strong Q2...
Wed, 02 Sep 2026 15:07:03 +0000